177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.

Abstract:

:177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncommon. The aim of this study was to improve the 177Lu-octreotate therapy by means of combination therapy. To identify radiosensitising inhibitors, two cell lines, GOT1 and P-STS, derived from small intestinal neuroendocrine tumours (SINETs), were screened with 1,224 inhibitors alone or in combination with external radiation. The screening revealed that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a synergistic fashion (GOT1; false discovery rate <3.2×10-11). The potential for Hsp90 inhibitor ganetespib to enhance the anti-tumour effect of 177Lu-octreotate in an in vivo setting was studied in the somatostatin receptor-expressing GOT1 xenograft model. The combination led to a larger decrease in tumour volume relative to monotherapies and the tumour-reducing effect was shown to be synergistic. Using patient-derived tumour cells from eight metastatic SINETs, we could show that ganetespib enhanced the effect of 177Lu-octreotate therapy for all investigated patient tumours. Levels of Hsp90 protein expression were evaluated in 767 SINETs from 379 patients. We found that Hsp90 expression was upregulated in tumour cells relative to tumour stroma in the vast majority of SINETs. We conclude that Hsp90 inhibitors enhance the tumour-killing effect of 177Lu-octreotate therapy synergistically in SINET tumour models and suggest that this potentially promising combination should be further evaluated.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

Hofving T,Sandblom V,Arvidsson Y,Shubbar E,Altiparmak G,Swanpalmer J,Almobarak B,Elf AK,Johanson V,Elias E,Kristiansson E,Forssell-Aronsson E,Nilsson O

doi

10.1530/ERC-18-0509

subject

Has Abstract

pub_date

2019-04-01 00:00:00

pages

437-449

issue

4

eissn

1351-0088

issn

1479-6821

pii

ERC-18-0509

journal_volume

26

pub_type

杂志文章
  • MINDIN secretion by prostate tumors induces premetastatic changes in bone via β-catenin.

    abstract::Bone metastases are common in advanced prostate cancer patients, but mechanisms by which specific pro-metastatic skeletal niches are formed before tumor cell homing are unclear. We aimed to analyze the effects of proteins secreted by primary prostate tumors on the bone microenvironment before the settlement and propag...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-20-0116

    authors: Ardura JA,Álvarez-Carrión L,Gutiérrez-Rojas I,Friedman PA,Gortázar AR,Alonso V

    更新日期:2020-07-01 00:00:00

  • Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

    abstract::The androgen receptor (AR) is well known to play a central role in the pathogenesis of prostate cancer (PCa). In several studies, AR was overexpressed in castration-resistant PCa (CRPC). However, the mechanism of AR overexpression in CRPC is not fully elucidated. Y-box binding protein-1 (YB-1) is a pleiotropic transcr...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0017

    authors: Shiota M,Takeuchi A,Song Y,Yokomizo A,Kashiwagi E,Uchiumi T,Kuroiwa K,Tatsugami K,Fujimoto N,Oda Y,Naito S

    更新日期:2011-07-11 00:00:00

  • Current mouse and cell models in prostate cancer research.

    abstract::Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa initiation, progression, and treatment modalities. Here, we summarize recent advances in PCa mouse models that led to new insights into specific gene functions in PCa. For example, the study of transgenic mice with TMPRSS2/ERG, an ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0285

    authors: Wu X,Gong S,Roy-Burman P,Lee P,Culig Z

    更新日期:2013-06-24 00:00:00

  • Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.

    abstract::Pancreatic endocrine tumors (PET) represent a heterogenous group of neoplasms. Although surgical resection is considered a safe and effective treatment for many PET, therapeutic options for inoperable and progressive PET are limited. The expression of heat-shock protein (HSP) 90 was investigated in 120 clinically and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0227

    authors: Mayer P,Harjung A,Breinig M,Fischer L,Ehemann V,Malz M,Scherübl H,Britsch S,Werner J,Kern MA,Bläker H,Schirmacher P,Bergmann F

    更新日期:2012-05-03 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract::Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060333

    authors: Boyce BF,Yoneda T,Guise TA

    更新日期:1999-09-01 00:00:00

  • Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue.

    abstract::Parathyroid carcinoma (PaC) is a rare cause of primary hyperparathyroidism. Though the loss of the oncosuppressor CDC73/HRPT2 gene product, parafibromin, has been involved in the hyperparathyroidism-jaw tumor syndrome and in a consistent set of sporadic PaCs, parathyroid carcinogenesis remains obscure. MicroRNAs are a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0134

    authors: Corbetta S,Vaira V,Guarnieri V,Scillitani A,Eller-Vainicher C,Ferrero S,Vicentini L,Chiodini I,Bisceglia M,Beck-Peccoz P,Bosari S,Spada A

    更新日期:2010-02-18 00:00:00

  • Metabolite analysis-aided diagnosis of papillary thyroid cancer.

    abstract::Thyroid cancer is the most frequent endocrine tumor with a growing incidence worldwide. However, common diagnostic strategy for thyroid cancer classification is hardly to make a proper diagnosis in some cases. To assist classical approach, this study used metabolomics to screen and validate biomarkers from serum and u...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0344

    authors: Chen J,Hu Q,Hou H,Wang S,Zhang Y,Luo Y,Chen H,Deng H,Zhu H,Zhang L,Liu H,Wang A,Liu Y

    更新日期:2019-12-01 00:00:00

  • A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: gene selection using support vector machines with bootstrapping.

    abstract::Selection of novel molecular markers is an important goal of cancer genomics studies. The aim of our analysis was to apply the multivariate bioinformatical tools to rank the genes - potential markers of papillary thyroid cancer (PTC) according to their diagnostic usefulness. We also assessed the accuracy of benign/mal...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-06-0048

    authors: Fujarewicz K,Jarzab M,Eszlinger M,Krohn K,Paschke R,Oczko-Wojciechowska M,Wiench M,Kukulska A,Jarzab B,Swierniak A

    更新日期:2007-09-01 00:00:00

  • The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).

    abstract::Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal hypersecretory syndrome. The clinical spectrum of NFpitNETs varies from completely asymptomatic to the development of panhypopituitarism an...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-20-0136

    authors: Yavropoulou MP,Tsoli M,Barkas K,Kaltsas G,Grossman A

    更新日期:2020-10-01 00:00:00

  • Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.

    abstract::Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects, depending on the tissue, cell, or promoter context. These mi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060271

    authors: Osborne CK

    更新日期:1999-06-01 00:00:00

  • Androgens, diabetes and prostate cancer.

    abstract::Metabolic disorders such as diabetes, obesity and the metabolic syndrome have been shown to modulate prostate cancer (PCa) risk and aggressiveness in population-based and experimental studies. While associations between these conditions are modest and complex, two consistent findings have emerged. First, there is obse...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0067

    authors: Grossmann M,Wittert G

    更新日期:2012-09-05 00:00:00

  • CUX1: a modulator of tumour aggressiveness in pancreatic neuroendocrine neoplasms.

    abstract::Pancreatic neuroendocrine neoplasms (PNENs) constitute a rare tumour entity, and prognosis and treatment options depend on tumour-mediating hallmarks such as angiogenesis, proliferation rate and resistance to apoptosis. The molecular pathways that determine the malignant phenotype are still insufficiently understood a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0152

    authors: Krug S,Kühnemuth B,Griesmann H,Neesse A,Mühlberg L,Boch M,Kortenhaus J,Fendrich V,Wiese D,Sipos B,Friemel J,Gress TM,Michl P

    更新日期:2014-01-01 00:00:00

  • Germline and somatic SDHx alterations in apparently sporadic differentiated thyroid cancer.

    abstract::Along with breast and endometrial cancers, thyroid cancer is a major component cancer in Cowden syndrome (CS). Germline variants in SDHB/C/D (SDHx) genes account for subsets of CS/CS-like cases, conferring a higher risk of breast and thyroid cancers over those with only germline PTEN mutations. To investigate whether ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0537

    authors: Ni Y,Seballos S,Ganapathi S,Gurin D,Fletcher B,Ngeow J,Nagy R,Kloos RT,Ringel MD,LaFramboise T,Eng C

    更新日期:2015-04-01 00:00:00

  • The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

    abstract::Imatinib mesylate (IM), a small molecule that is a selective inhibitor of the ABL, platelet derived growth factor receptor (PDGFR-R) and stem cell ligand receptor (c-kit) tyrosine kinases (TK). IM was also found to inhibit the TK activity of BCR/ABL fusion protein produced in chronic myelogenous leukemia, with marked ...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1677/erc.1.01124

    authors: Gross DJ,Munter G,Bitan M,Siegal T,Gabizon A,Weitzen R,Merimsky O,Ackerstein A,Salmon A,Sella A,Slavin S,Israel Glivec in Solid Tumors Study Group.

    更新日期:2006-06-01 00:00:00

  • Thyrotoxicosis with concomitant thyroid cancer.

    abstract::Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0129

    authors: Fu H,Cheng L,Jin Y,Chen L

    更新日期:2019-07-01 00:00:00

  • Metabolomics signatures of a subset of RET variants according to their oncogenic risk level.

    abstract::Thirty percent of medullary thyroid carcinomas (MTCs) are related to dominant germline pathogenic variants in the RET proto-oncogene. According to their aggressiveness, these pathogenic variants are classified in three risk levels: 'moderate', 'high' and 'highest'. The present study compares the metabolomics profiles ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0314

    authors: Veyrat-Durebex C,Bouzamondo N,Le Mao M,Chao de la Barca JM,Bris C,Dieu X,Simard G,Gadras C,Tessier L,Drui D,Borson-Chazot F,Barlier A,Reynier P,Prunier-Mirebeau D

    更新日期:2019-03-01 00:00:00

  • Sporadic hypercalcitoninemia: clinical and therapeutic consequences.

    abstract::'Calcitonin screening' is not accepted as the standard of care in daily practice. The clinical and surgical consequences of 'calcitonin screening' in a series of patients with mildly elevated basal calcitonin and pentagastrin stimulated calcitonin levels are presented. 260 patients with elevated basal (>10 pg/ml) and ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-08-0059

    authors: Scheuba C,Kaserer K,Moritz A,Drosten R,Vierhapper H,Bieglmayer C,Haas OA,Niederle B

    更新日期:2009-03-01 00:00:00

  • HES5 silencing is an early and recurrent change in prostate tumourigenesis.

    abstract::Prostate cancer is the most common cancer in men, resulting in over 10 000 deaths/year in the UK. Sequencing and copy number analysis of primary tumours has revealed heterogeneity within tumours and an absence of recurrent founder mutations, consistent with non-genetic disease initiating events. Using methylation prof...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0454

    authors: Massie CE,Spiteri I,Ross-Adams H,Luxton H,Kay J,Whitaker HC,Dunning MJ,Lamb AD,Ramos-Montoya A,Brewer DS,Cooper CS,Eeles R,UK Prostate ICGC Group.,Warren AY,Tavaré S,Neal DE,Lynch AG

    更新日期:2015-04-01 00:00:00

  • Trp63 is regulated by STAT5 in mammary tissue and subject to differentiation in cancer.

    abstract::Transformation-related protein 63 (Trp63), the predominant member of the Trp53 family, contributes to epithelial differentiation and is expressed in breast neoplasia. Trp63 features two distinct promoters yielding specific mRNAs encoding two major TRP63 isoforms, a transactivating transcription factor and a dominant n...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0032

    authors: Assefnia S,Kang K,Groeneveld S,Yamaji D,Dabydeen S,Alamri A,Liu X,Hennighausen L,Furth PA

    更新日期:2014-05-06 00:00:00

  • Acquired resistance to aromatase inhibitors: where we stand!

    abstract::Aromatase inhibitors (AIs) are one of the principal therapeutic approaches for estrogen receptor-positive (ER+) breast cancer in postmenopausal women. They block estrogen biosynthesis through aromatase inhibition, thus preventing tumour progression. Besides the therapeutic success of the third-generation AIs, acquired...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0425

    authors: Augusto TV,Correia-da-Silva G,Rodrigues CMP,Teixeira N,Amaral C

    更新日期:2018-05-01 00:00:00

  • Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction.

    abstract::Quantitative reverse transcription-polymerase chain reaction (RT-PCR) used to detect minor changes in specific mRNA concentrations may be associated with poor reproducibility. Stringent quality control is therefore essential at each step of the protocol, including the PCR procedure. We performed inter-laboratory quali...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.00808

    authors: de Cremoux P,Bieche I,Tran-Perennou C,Vignaud S,Boudou E,Asselain B,Lidereau R,Magdelénat H,Becette V,Sigal-Zafrani B,Spyratos F

    更新日期:2004-09-01 00:00:00

  • Overview of tyrosine kinase inhibitors in clinical breast cancer.

    abstract::Studies of cell models and profiling of clinical breast cancer material to reveal the mechanisms of resistance to anti-oestrogen therapy, and to tamoxifen in particular, have reported that this phenomenon can be associated with increased expression and signalling through erbB Type 1 growth factor receptors, notably th...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01059

    authors: Agrawal A,Gutteridge E,Gee JM,Nicholson RI,Robertson JF

    更新日期:2005-07-01 00:00:00

  • Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases.

    abstract::This review focuses on the tumour types and symptoms associated with non-islet cell tumour-induced hypoglycaemia (NICTH) as well as the pathogenesis, diagnosis and treatment of this rare paraneoplastic phenomenon. In addition, we report two illustrative cases of patients suffering from NICTH caused by a solid fibrous ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0161

    authors: de Groot JW,Rikhof B,van Doorn J,Bilo HJ,Alleman MA,Honkoop AH,van der Graaf WT

    更新日期:2007-12-01 00:00:00

  • CD74 expression and its therapeutic potential in thyroid carcinoma.

    abstract::CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0269

    authors: Cheng SP,Liu CL,Chen MJ,Chien MN,Leung CH,Lin CH,Hsu YC,Lee JJ

    更新日期:2015-04-01 00:00:00

  • Role of hypoxia-inducible factor-1alpha as a cancer therapy target.

    abstract::Hypoxia occurs in solid tumours due to a mismatch between tumour growth and angiogenesis. Hypoxia in solid tumours is associated with an aggressive phenotype and resistance to radiation therapy and chemotherapy leading to poor patient prognosis. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor, which is ac...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.1.01290

    authors: Patiar S,Harris AL

    更新日期:2006-12-01 00:00:00

  • A MUTYH germline mutation is associated with small intestinal neuroendocrine tumors.

    abstract::The genetics behind predisposition to small intestinal neuroendocrine tumors (SI-NETs) is largely unknown, but there is growing awareness of a familial form of the disease. We aimed to identify germline mutations involved in the carcinogenesis of SI-NETs. The strategy included next-generation sequencing of exome- and/...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0196

    authors: Dumanski JP,Rasi C,Björklund P,Davies H,Ali AS,Grönberg M,Welin S,Sorbye H,Grønbæk H,Cunningham JL,Forsberg LA,Lind L,Ingelsson E,Stålberg P,Hellman P,Tiensuu Janson E

    更新日期:2017-08-01 00:00:00

  • Effect of hormone secretory syndromes on neuroendocrine tumor prognosis.

    abstract::The treatment of hormone hypersecretory syndromes caused by neuroendocrine tumors (NETs) can be a major challenge. NETs originating from the small intestine often secrete serotonin causing flushing, diarrhea and valve fibrosis, leading to dehydration or heart failure in severe cases. NETs from the pancreas can secrete...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0538

    authors: Zandee WT,Kamp K,van Adrichem RC,Feelders RA,de Herder WW

    更新日期:2017-07-01 00:00:00

  • A novel role of Shc adaptor proteins in steroid hormone-regulated cancers.

    abstract::Tyrosine phosphorylation plays a critical role in growth regulation, and its aberrant regulation can be involved in carcinogenesis. The association of Shc (Src homolog and collagen homolog) adaptor protein family members in tyrosine phosphorylation signaling pathway is well recognized. Shc adaptor proteins transmit ac...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-08-0179

    authors: Alam SM,Rajendran M,Ouyang S,Veeramani S,Zhang L,Lin MF

    更新日期:2009-03-01 00:00:00

  • FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5.

    abstract::Ovarian epithelial cancer is the leading cause of death among gynecological malignancies. FSH may increase the risk of ovarian malignancy and play an important role in ovarian carcinogenesis. Our previous studies showed that FSH increases the expression of VEGF through survivin. In this study, the function and mechani...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-09-0308

    authors: Huang Y,Jin H,Liu Y,Zhou J,Ding J,Cheng KW,Yu Y,Feng Y

    更新日期:2010-11-30 00:00:00

  • Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.

    abstract::The clinical course of medullary thyroid carcinoma (MTC) associated with the MEN2A syndrome as well as of sporadic MTC shows considerable heterogeneity. The disease picture varies not only between the same RET proto-oncogene mutation carriers but also among sporadic MTC patients with no RET germinal mutations, which s...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0452

    authors: Kaczmarek-Ryś M,Ziemnicka K,Pławski A,Budny B,Michalak M,Hryhorowicz S,Hoppe-Gołębiewska J,Boruń P,Gołąb M,Czetwertyńska M,Sromek M,Szalata M,Ruchała M,Słomski R

    更新日期:2018-04-01 00:00:00